Patents by Inventor Michael Sperzel

Michael Sperzel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090170766
    Abstract: The present invention relates to chimeras of human tissue factor inhibitor domain 1 with natural and non-natural Kunitz domains, and their preparation and use.
    Type: Application
    Filed: March 1, 2007
    Publication date: July 2, 2009
    Applicant: BAYER HEALTHCARE AG
    Inventors: Felix Oehme, Heiner Apeler, Frank Dittmer, Jürgen Franz, Axel Harrenga, Michael Sperzel, Simone Greven, Jürgen Lenz
  • Patent number: 6867206
    Abstract: The present invention relates to 6-carboxyphenyldihydropyridazinone derivatives having the formula wherein R1, R2, R3, A, D, G, and E are as defined in the specification and claims, a process for preparing these materials, pharmaceutical compositions containing them, and a method for using them in the treatment of anemias.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: March 15, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Jürgen Stoltefuss, Gabriele Bräunlich, Michael Lögers, Carsten Schmeck, Ulrich Nielsch, Martin Bechem, Christoph Gerdes, Michael Sperzel, Klemens Lustig, Werner Stürmer
  • Patent number: 6699857
    Abstract: The invention relates to the area of erythropoiesis, in particular to the use of tetrahydroquinolinyl-6-methyldihydrothiadiazinones of general formula (I) for treating anaemia. The invention also relates to novel tetrahydroquinolinyl-6-methyldihydrothiadiazinone derivatives and to the production thereof.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: March 2, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Jürgen Stoltefuss, Gabriele Bräunlich, Michael Lögers, Carsten Schmeck, Ulrich Nielsch, Martin Bechem, Christoph Gerdes, Michael Sperzel, Klemens Lustig, Werner Stürmer
  • Patent number: 6677372
    Abstract: N-(3-benzofuranyl)urea-derivatives are prepared by reacting of 3-amino-substituted benzofuranes with appropriate substituted isocyanates or isothiocyanates. The N(3-benzofuranyl)urea-derivatives can be used as active ingredients in medicaments particularly for the treatment of acute and chronic inflammatory processes.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: January 13, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Gabriele Bräunlich, Rüdiger Fischer, Mazen Es-Sayed, Rolf Henning, Michael Sperzel, Karl-Heinz Schlemmer, Ulrich Nielsch, Stephen Tudhope, Graham Sturton, Trevor S. Abram, Mary F. Fitzgerald
  • Patent number: 6610687
    Abstract: The invention relates to benzofuranylsulfonates of the general formula (I), their preparation and their use for the treatment of inflammation.
    Type: Grant
    Filed: February 25, 2002
    Date of Patent: August 26, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Gabriele Bräunlich, Mazen Es-Sayed, Rüdiger Fischer, Burkhard Fugmann, Rolf Henning, Stephan Schneider, Michael Sperzel, Karl-Heinz Schlemmer, Graham Sturton, Mary F. Fitzgerald, Barbara Briggs, Arnel Concepcion, William Bullock
  • Publication number: 20030109578
    Abstract: N-(3-benzofuranyl)urea-derivatives are prepared by reacting of 3-amino-substituted benzofuranes with appropriate substituted isocyanates or isothiocyanates. The N(3-benzofuranyl)urea-derivatives can be used as active ingredients in medicaments particularly for the treatment of acute and chronic inflammatory processes.
    Type: Application
    Filed: May 24, 2002
    Publication date: June 12, 2003
    Inventors: Gabriele Braunlich, Rudiger Fischer, Mazen Es-Sayed, Rolf Henning, Michael Sperzel, Karl-Heinz Schlemmer, Ulrich Nielsch, Stephen Tudhope, Graham Sturton, Trevor S. Abram, Mary F. Fitzgerald
  • Patent number: 6506734
    Abstract: The present invention relates to glycoconjugates of 20(S)-camptothecin, in which a 3-O-methylated &bgr;-L-fucose unit is linked to the 20-hydroxyl group of a camptothecin derivative via a thiourea-modified peptide spacer. The invention furthermore relates to processes for the preparation of the compounds according to the invention and to their use as medicaments, in particular in connection with oncoses.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: January 14, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Hans-Georg Lerchen, Karsten von dem Bruch, Jörg Baumgarten, Michael Sperzel
  • Patent number: 6492335
    Abstract: The present invention relates to glycoconjugates of camptothecin derivatives in which at least one carbohydrate component is linked via suitable spacers with the 20-hydroxyl group of a camptothecin derivative. The invention furthermore relates to processes for preparing the compounds according to the invention and to their use as medicaments, in particular in connection with cancer.
    Type: Grant
    Filed: March 24, 1999
    Date of Patent: December 10, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Hans-Georg Lerchen, Karsten von dem Bruch, Jörg Buamgarten, Michael Sperzel
  • Publication number: 20020173468
    Abstract: The present invention relates to conjugates of cytostatics and N-thiocarbonyl-modified amino acids or peptides, processes for their preparation and their use as medicaments, in particular in connection with carcinomatous disorders.
    Type: Application
    Filed: June 7, 1999
    Publication date: November 21, 2002
    Inventors: HANS-GEORG LERCHEN, KARSTEN VON DEM BRUCH, JORG BAUMGARTEN, MICHAEL SPERZEL
  • Patent number: 6399657
    Abstract: N-(3-benzofuranyl)urea-derivatives are prepared by reacting of 3-amino-substituted benzofuranes with appropriate substituted isocyanates or isothiocyanates. The N(3-benzofuranyl)urea-derivatives can be used as active ingredients in medicaments particularly for the treatment of acute and chronic inflammatory processes.
    Type: Grant
    Filed: May 21, 1999
    Date of Patent: June 4, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Gabriele Bräunlich, Rüdiger Fischer, Mazen Es-Sayed, Rolf Henning, Michael Sperzel, Karl-Heinz Schlemmer, Ulrich Nielsch, Stephen Tudhope, Graham Sturton, Trevor S. Abram, Mary F. Fitzgerald
  • Patent number: 6271342
    Abstract: The invention relates to cytostatics which, by modification with sugar, are tumor-specific. Suitable spacers ensure serum stability and at the same time an intracellular action.
    Type: Grant
    Filed: September 25, 1997
    Date of Patent: August 7, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Hans-Georg Lerchen, Karsten von dem Bruch, Uwe Petersen, Jörg Baumgarten, Norbert Piel, Horst-Peter Antonicek, Walter Weichel, Michael Sperzel, Klaus Dieter Bremm
  • Patent number: 6169092
    Abstract: 3-Urea-pyridofurans and -pyridothiophenes are prepared by reacting appropriately substituted 3-amino-pyridofurans or -pyridothiophenes with isocyanates or isothiocyanates. The 3-urea-pyridofurans and -pyridothiophenes can be used as active ingredients in medicaments, particularly in medicaments for the treatment of acute and chronic inflammatory processes.
    Type: Grant
    Filed: January 5, 1999
    Date of Patent: January 2, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Gabriele Br{umlaut over (a)}unlich, Mazen Es-Sayed, R{umlaut over (u)}diger Fischer, Rolf Henning, Burkhard Fugmann, Stephan Schneider, Michael Sperzel, Graham Sturton, Mary Fitzgerald, Barbara Briggs, Arnel Concepcion
  • Patent number: 6156754
    Abstract: The present invention relates to glycoconjugates of camptothecin derivatives in which at least one carbohydrate component is linked via suitable spacers with the A or B ring of a camptothecin derivative. The invention furthermore relates to processes for preparing the compounds according to the invention and to their use as medicaments, in particular in connection with cancer.
    Type: Grant
    Filed: March 24, 1999
    Date of Patent: December 5, 2000
    Assignee: Bayer Aktiengesellschaft
    Inventors: Hans-Georg Lerchen, Karsten von dem Bruch, Jorg Baumgarten, Michael Sperzel
  • Patent number: 5922740
    Abstract: Heterocyclyclcarbonyl substituted benzofuranyl-ureas are prepared by reacting heterocyclylcarbonyl substituted 3-amino-benzofuranes with appropriate isocyanates or isothiocyanates. The unsubstituted ureas are transferred into substituted ureas by usual methods of substitution. The heterocyclylcarbonyl substituted benzofuranyl-ureas are useful as active ingredients in medicaments particularly for the treatment of acute and chronical inflammatory processes.
    Type: Grant
    Filed: December 4, 1996
    Date of Patent: July 13, 1999
    Assignee: Bayer Aktiengesellschaft
    Inventors: Gabriele Braunlich, Mazen Es-Sayed, Rudiger Fischer, Burkhardt Fugmann, Rolf Henning, Michael Sperzel, Ulrich Nielsch, Graham Sturton
  • Patent number: 5510365
    Abstract: The invention relates to the use of 1-thiocarbamoyl-5-hydroxypyrazoles of the general formula ##STR1## in which the substituents denote the radicals mentioned in the description, as pharmaceutical agents for combating septic shock and the consequences thereof.
    Type: Grant
    Filed: August 4, 1994
    Date of Patent: April 23, 1996
    Assignee: Bayer Aktiengesellschaft
    Inventors: Peter Wachtler, Lutz Heuer, Michael Sperzel, Klaus G. Stunkel
  • Patent number: 5091364
    Abstract: A process for the preparation of glycoproteins and proteins from cultures of archaebacteria, comprising culturing archaebacteria, isolating glycoprotein and/or protein from the archaebacteria or their cell walls, enzymatically degrading the glycoprotein and/or protein, purifying and isolating the degradation products, and separating those fractions in the individual purification steps based on the biological activity of the fraction. The products increase the body's defenses against infection.
    Type: Grant
    Filed: July 25, 1990
    Date of Patent: February 25, 1992
    Assignee: Bayer Aktiengesellschaft
    Inventors: Jorg Baumgarten, Helmut Brunner, Inge Flesch, Heinz Hildebrand, Norbert Piel, Michael Sperzel
  • Patent number: 5070190
    Abstract: The invention relates to new N-glycosylamides of the general formula I ##STR1## in which R.sup.1 denotes a saturated alkyl radical or a singly, doubly or triply unsaturated alkenyl radical having up to 50 carbon atoms,R.sup.2 denotes a saturated alkyl radical or a singly, doubly or triply unsaturated alkenyl radical having up to 50 carbon atoms,A represents --CO-- or represents a group ##STR2## in which R.sup.3 represents hydrogen, C.sub.1 -C.sub.7 alkyl, hydroxymethyl, 1-hydroxyethyl, mercaptomethyl, 2-methylthioethyl, 3-aminopropyl, 2-ureidopropyl, 3-guanidylpropyl, 4-aminobutyl, carboxymethyl, carbamoylmethyl, 2-carboxyethyl, 2-carbamoylethyl, benzyl, 4-hydroxybenzyl, 3-indolylmethyl or 4-imidazolylmethyl, andn represents 0 to 10,and which are substituted in the sugar residue with an amino acid residue, as well as process for their preparation and their use as medicaments.
    Type: Grant
    Filed: April 12, 1989
    Date of Patent: December 3, 1991
    Assignee: Bayer Aktiengesellschaft
    Inventors: Oswald Lockhoff, John Goossens, Helmut Brunner, Michael Sperzel, Klaus G. Stunkel